We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




A Breath-Analysis Test for Rapid Diagnosis of COVID-19

By LabMedica International staff writers
Posted on 09 Nov 2020
Researchers have reported the development of a rapid breath-analysis test that detects COVID-19 by identifying significant changes in the exhaled concentrations of a panel of volatile organic compounds. More...


There is an urgent need to rapidly distinguish COVID-19 from other respiratory conditions, including influenza. Point-of-care tests not requiring laboratory support will speed diagnosis and reduce exposure to those infected with the coronavirus.

In this regard, investigators at Loughborough University (United Kingdom) and collaborators at the IMSPEX Group (Abercynon, United Kingdom) and other sites in the United Kingdom and Germany evaluated the feasibility of using breath-analysis to distinguish these conditions with near-patient gas chromatography-ion mobility spectrometry (GC-IMS).

For the feasibility study, a group of 98 patients were recruited in Edinburgh, the United Kingdom, and Dortmund, Germany. Among this group, 31 patients had COVID-19, as diagnosed by RT- qPCR analysis of oral/nasal swabs. The other patients were diagnosed with asthma, exacerbation of asthma and COPD, viral pneumonia, other respiratory tract infections, and cardiac conditions.

A single breath-sample from each patient was tested for volatile organic compounds (VOCs) using the IMSPEX BreathSpec GC-IMS analyzer. Multivariate analysis identified aldehydes (ethanal, octanal), ketones (acetone, butanone), and methanol that discriminated COVID-19 from other conditions. An unidentified-feature with significant predictive power for severity/death was isolated in Edinburgh, while heptanal was identified in Dortmund. Differentiation of patients with definite diagnosis of COVID-19 from non-COVID-19 was possible with 80% and 81.5% accuracy in Edinburgh and Dortmund, respectively.

Contributing author, Dr. Paul Thomas, professor of analytical science at Loughborough University, said, "We are hugely encouraged by these findings. Employing tried and tested techniques used during the TOXI-Triage project, suggests that COVID-19 may be rapidly distinguished from other respiratory conditions. To develop this technique further larger studies are required, together with complementary GC-MS studies, to build on the data collected so far. If shown to be reliable, it offers the possibility for rapid identification or exclusion of COVID-19 in emergency departments or primary care that will protect healthcare staff, improve the management of patients, and reduce the spread of COVID-19."

The breath-analysis test for rapid diagnosis of COVID-19 was described in the October 24, 2020, online edition of the journal EClinicalMedicine.

Related Links:
Loughborough University
IMSPEX Group



Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: How the predictive test works (Photo courtesy of QMUL)

World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment

Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.